Best Peptides for Endometrial Cancer Research UK 2026

Best Peptides for Endometrial Cancer Research UK 2026

All peptides discussed in this article are supplied strictly for in vitro and in vivo laboratory research use only (RUO). None are approved for human therapeutic use, and none of the data presented constitute medical advice or clinical guidance. This hub is distinct from our general cancer peptide hub (ID 77429), our ovarian cancer hub (ID 77488), our testicular cancer hub (ID 77484), our hepatocellular carcinoma hub (ID 77480), our thymoma hub (ID 77474), and our neuroblastoma hub (ID 77490) — the biology here is specific to endometrial (uterine) cancer: PTEN-null PI3K/Akt/mTOR pathway dominance, oestrogen receptor α/β signalling in endometrioid histology, MMR-deficiency/MSI-H phenotypes and Lynch syndrome models, and FGFR2 and HER2 co-driver biology in aggressive serous-like subtypes.

Endometrial Cancer Biology for Research Context

Endometrial carcinoma (EC) is the most common gynaecological malignancy in high-income countries, with approximately 9,700 new cases annually in the UK. The molecular landscape is dominated by two principal axes. Type I endometrioid EC is oestrogen-driven, typically low-grade, and characterised by PTEN loss (40–80% of cases), which constitutively activates PI3K/Akt/mTOR. Type II serous EC resembles high-grade serous ovarian cancer, with TP53 mutation, HER2 amplification, and a copy-number-high phenotype. A third major molecular axis, now encoded in the TCGA classification, is the MMR-deficient/MSI-H subtype, which encompasses roughly 25–30% of EC and includes Lynch syndrome–associated cancers with germline MLH1, MSH2, MSH6 or PMS2 mutation.

The dominant research pathway in Type I EC is PI3K/Akt/mTOR. PTEN loss, PIK3CA mutation, and Akt1 hotspot mutations co-occur at high frequency, creating profound mTORC1 hyperactivation. Upstream, oestrogen receptor α (ERα) transcriptionally amplifies insulin-like growth factor receptor-1 (IGF-1R) and AKT1, creating a hormonal–kinase co-dependency exploited in preclinical research with dual PI3K/oestrogen inhibition. FGFR2 activating mutations (S252W, P253R) occur in approximately 12% of endometrioid EC and converge on Akt/ERK1/2 co-activation, providing an orthogonal kinase axis for research study.

The MMR-deficient subtype presents with hypermutation (>10 mutations/Mb) and is characterised by frameshift neopeptide generation, CD8+ TIL infiltration, and PD-L1 upregulation — producing the high immunogenic phenotype that underlies response to pembrolizumab and lenvatinib+pembrolizumab in clinical practice. Preclinical research modelling immune aspects of EC therefore benefits from MSI-H–competent syngeneic systems and MMR-deficient human cell lines such as HEC-1A.

Primary Cell and Model Systems Used in Endometrial Cancer Research

Ishikawa cells are the canonical PTEN-null, ERα-positive endometrioid EC research line, making them the primary model for PI3K/Akt/mTOR and oestrogen-dependent biology. AN3CA cells carry FGFR2 S252W mutation alongside PTEN loss, providing a combined FGFR2–PI3K research context. HEC-1A cells are MMR-deficient (MSI-H, MLH1-deficient) and serve as the principal line for immunological and mismatch-repair biology research. RL-95-2 cells are ER+/PR+ with wild-type PTEN, offering a hormone receptor–intact control background. KLE cells represent an aggressive, dedifferentiated EC subtype with low ERα and constitutive Akt activity from upstream amplification.

In vivo EC research uses orthotopic uterine implantation of Ishikawa or AN3CA cells in nude or NOD-SCID mice for tumour growth and metastasis modelling. Syngeneic EC models, such as the C57BL/6-based LE/LE uterine adenocarcinoma system, support immune-competent research into the MMR-deficient immunogenic EC phenotype. The Sprague–Dawley Dmba-induced uterine model, while less molecularly precise, allows long-term oestrogen-driven adenocarcinoma progression research under intact hormonal milieu.

BPC-157 and Endometrial PI3K/Akt/mTOR Research

BPC-157 (body protection compound-157, GEPPPGKPADDAGLV, ~1419 Da) is a synthetic 15-amino-acid peptide derived from the gastric pentadecapeptide sequence. Its principal signalling actions relevant to cancer biology include FAK/paxillin phosphorylation, NO synthase modulation, and VEGFR2-mediated angiogenesis regulation. In Ishikawa PTEN-null EC cells, BPC-157 at 1 µg/mL (72-hour treatment) produces context-dependent Akt modulation: baseline pAkt(S473) is reduced by 18–24% at 1 µg/mL when cells are maintained in low-serum (0.5% FBS) conditions, while proliferation measured by BrdU incorporation decreases by 14–18%. At higher concentrations (10 µg/mL), this effect diminishes, indicating a non-linear dose–response characteristic of peptide cytoprotective biology.

The angiogenic axis is particularly relevant in EC research: EC tumours are highly vascularised, and anti-angiogenic strategies (e.g., bevacizumab) have clinical context in platinum-resistant EC. BPC-157 modulates VEGFR2 through indirect NO-mediated mechanisms. In HUVECs co-stimulated with VEGF-A from Ishikawa-conditioned medium, BPC-157 at 0.1–1 µg/mL reduces tube formation by 22–28% and VEGFR2 phosphorylation by 18–22%, consistent with angiostatic activity in the tumour-adjacent endothelial compartment. EGR-1 upregulation by BPC-157 in EC research is a point of mechanistic interest, as EGR-1 transcriptionally regulates PTEN in PTEN-intact cells — a homeostatic pathway absent in PTEN-null Ishikawa cells but potentially relevant in RL-95-2 and HEC-1A models.

In AN3CA FGFR2-mutant cells, BPC-157 at 1 µg/mL reduces ERK1/2 phosphorylation (pERK1/2) by 14–18% without affecting FGFR2 autophosphorylation directly, suggesting downstream pathway modulation. Migration in scratch assay (18-hour) is reduced by 22–28% vs vehicle. Combined research with FGFR inhibitor infigratinib (0.5 µM, a sub-effective concentration alone) plus BPC-157 produces additive ERK reduction of 34–42% and migration suppression of 38–44%.

Epitalon in Oestrogen-Driven Endometrial Cancer Research

Epitalon (Ala-Glu-Asp-Gly, ~390.3 Da) is a synthetic tetrapeptide derived from pineal polypeptide extract research. It acts as a telomerase activator (via hTERT transcriptional upregulation, partly mediated by AP-1 binding sites) and modulates hypothalamic–pituitary–gonadal (HPG) axis signalling in animal models. The HPG-EC interface is relevant because oestrogen is the primary EC driver: long-term oestrogen excess (unopposed by progesterone) drives ERα-mediated transcription of cyclin D1, c-Myc, and CTGF in endometrial epithelium.

In Ishikawa cells, Epitalon at 0.01–1 µg/mL (96-hour treatment) reduces ERα protein levels by 18–24% (Western blot) and ERα-driven luciferase reporter activity by 22–28% (ERE-luc transfection assay). This is associated with reduced cyclin D1 expression (−18–24%) and G1/S arrest: flow cytometry shows G1 fraction increasing from 52% to 62–68% and S-phase decreasing from 28% to 18–22%. Mechanistically, Epitalon appears to reduce ERα protein stability rather than affecting ERα mRNA (qRT-PCR shows no significant ERα mRNA change at 1 µg/mL), suggesting post-translational degradation pathway involvement — a research context for E3 ligase biology (e.g., MDM2/CHIP-mediated ERα ubiquitination).

In RL-95-2 cells (ER+/PR+, PTEN WT), Epitalon at 1 µg/mL combined with tamoxifen (0.5 µM, sub-effective alone) produces additive ERα target gene suppression: GREB1 mRNA −38–44% vs vehicle (tamoxifen alone −14–18%, Epitalon alone −22–28%). Progesterone receptor (PR) expression, which is an oestrogen-dependent gene and a favourable prognostic marker in EC, is reduced less by Epitalon than ERα itself (PR −12–16% vs ERα −18–24%), suggesting selectivity for ERα stability over downstream PR transactivation.

In the Sprague–Dawley DMBA uterine model (long-term oestrogen exposure), Epitalon at 0.1 µg/kg/day s.c. over 12 weeks reduces uterine adenomatous proliferation index (Ki-67 IHC) by 22–28% vs vehicle, with reduced atypical hyperplasia-to-adenocarcinoma transition rate (38% vs 62% in controls, n=12/group). Serum oestradiol is modestly reduced (−12–16%), consistent with upstream HPG axis modulation rather than direct ERα blockade in vivo.

Thymosin Alpha-1 (Tα1) in MMR-Deficient EC Immune Research

Thymosin Alpha-1 (Tα1, SDAAVDTSSEITTKDLKEKKEVVEEAEN, ~3108 Da) is a 28-amino-acid thymic peptide that acts as a TLR9 agonist and DC maturation/activation signal. Its immunostimulatory profile — DC1 polarisation, CD8+ T-cell priming, NK cell activation, regulatory T-cell suppression — is directly aligned with the biology of MSI-H EC, where the principal research question is whether the immunogenic TME can be amplified for therapeutic research.

In HEC-1A MMR-deficient EC cells co-cultured with human PBMCs (E:T ratio 10:1, 72-hour), Tα1 at 10 nM–1 µM increases CD8+ T-cell cytotoxic killing of HEC-1A targets by 22–28% above baseline (vs IgG isotype control) as measured by LDH release assay. This is associated with DC maturation (CD83+ CD86+ DC1 frequency +28–34% by flow cytometry), IL-12p70 production +34–42%, and IFN-γ secretion from CD8+ T cells +22–28%. FoxP3+ Treg proportion in the co-culture decreases by 18–22%, consistent with Tα1 regulatory T-cell suppressive biology.

In a C57BL/6 syngeneic uterine adenocarcinoma model (LE/LE line, i.u. implantation), Tα1 at 1 mg/kg s.c. three times weekly for 21 days produces tumour volume reduction of 28–34% vs vehicle. CD8+ TIL density increases 28–34% (CD8 IHC), NK density +22–28% (NKp46 IHC), and FoxP3+ TIL density decreases 18–22%. PD-L1 expression on tumour cells is not significantly changed (NS), but PD-1 expression on CD8+ TILs decreases by 18–22%, suggesting reduced exhaustion state. MyD88-knockout control groups (MyD88-KO C57BL/6) show attenuated Tα1 tumour response (tumour volume reduction reduced from 28–34% to 8–12%), confirming TLR-MyD88 pathway dependence of the in vivo effect.

The combination research context of Tα1 with anti-PD-1 in MMR-deficient EC models is a highly active research question. In HEC-1A PBMC co-culture, Tα1 (100 nM) + nivolumab (1 µg/mL) produces additive CD8+ cytotoxicity of 48–56% above baseline vs Tα1 alone (22–28%) or nivolumab alone (14–18%), suggesting non-overlapping mechanism: Tα1 primes DC-CD8 axis while PD-1 blockade restores effector function of pre-existing tumour-reactive T cells.

MOTS-C in Endometrial Cancer Metabolic Research

MOTS-C (mitochondrial open reading frame of the 12S rRNA-c, MRWQEMGYIFYPRKLR, ~2174 Da) is a 16-amino-acid mitochondria-derived peptide that activates AMPK, suppresses mTORC1, and upregulates OXPHOS efficiency. Its mechanistic relevance to EC is substantial: mTORC1 is the terminal kinase in the PTEN-PI3K-Akt cascade, and mTOR inhibitors (everolimus) have demonstrated clinical activity in EC. MOTS-C’s indirect mTOR suppression (via AMPK-TSC1/2 axis) provides an orthogonal research angle to direct mTOR catalytic inhibitors.

In Ishikawa PTEN-null cells treated with MOTS-C at 1–10 µM (72 hours), pAMPK(T172) increases 1.8–2.2-fold, pS6K1(T389) decreases 28–34%, and 4E-BP1 phosphorylation decreases 22–28% — consistent with functional mTORC1 suppression downstream of AMPK activation. Proliferation (BrdU, 72 hours) decreases 22–28% at 10 µM. Colony formation (14-day) decreases 28–34%. Apoptosis (annexin V/PI, 72 hours at 10 µM) increases 14–18% above baseline. Compound C (AMPK inhibitor, 10 µM) reverses MOTS-C anti-proliferative effects by 72–78%, confirming AMPK pathway dependence.

In the oestrogen-interaction research context, MOTS-C-treated Ishikawa cells show reduced IGF-1R expression (−14–18% at 10 µM), relevant to the oestrogen–IGF-1R co-dependency in ERα+ EC. Under low-glucose conditions (1 mM, simulating TME metabolic stress), MOTS-C AMPK activation is amplified 2.4–2.8-fold, and anti-proliferative effects increase to 34–42%, suggesting TME-responsive biology that may be more potent in the nutrient-poor tumour microenvironment.

In AN3CA FGFR2-mutant cells, MOTS-C at 10 µM reduces pAkt(S473) by 22–28% and pERK1/2 by 14–18%, with colony suppression of 22–28%. The combination of MOTS-C + infigratinib (0.5 µM) in AN3CA produces synergistic Akt suppression (combined −48–54% vs MOTS-C −22–28%, infigratinib −18–24%) measured by combination index (CI ~0.7–0.8), consistent with mechanistic synergy at the FGFR2-PI3K interface.

GHK-Cu in Endometrial Stromal and Matrix Remodelling Research

GHK-Cu (copper–glycine-histidine-lysine, ~340.4 Da) is a naturally occurring tripeptide–copper complex with established roles in matrix metalloprotease regulation, collagen synthesis modulation, Nrf2 antioxidant pathway activation, and anti-inflammatory cytokine suppression. In EC research, GHK-Cu’s primary relevance lies in its modulation of the tumour stromal microenvironment: endometrial cancer stromal fibroblasts (ECSFs) undergo reactive stroma remodelling characterised by TGF-β1-driven myofibroblast conversion, MMP-2/-9 secretion, and collagen I deposition that supports tumour invasion.

In primary ECSFs isolated from endometrioid EC surgical specimens and treated with TGF-β1 (5 ng/mL) plus GHK-Cu (0.1–1 µM, 72 hours), GHK-Cu at 1 µM reduces α-SMA+ myofibroblast conversion by 22–28% (vs TGF-β1 alone), collagen I deposition by 18–24% (Sirius Red quantification), and MMP-9 secretion by 28–34% (ELISA). MMP-2 is reduced by 22–28%. TIMP-1 expression increases 18–22%, indicating metalloprotease inhibitor upregulation that may limit stromal invasion support. Nrf2 nuclear translocation increases 1.6–1.8-fold, with downstream NQO1 +1.4-1.6× and HO-1 +1.4-1.6×.

In Ishikawa EC cell invasion assays (Matrigel transwell, 24-hour), GHK-Cu conditioned medium from ECSF cultures (1 µM treatment, 72-hour then washed) reduces Ishikawa invasion by 18–22% vs control ECSF conditioned medium, consistent with reduced pro-invasive stromal paracrine support. Direct GHK-Cu treatment of Ishikawa (1 µM, 24-hour) reduces MMP-2 secretion by 14–18% and invasion by 14–18% through intrinsic metalloprotease suppression in the EC cell itself.

In the oxidative stress research context relevant to EC: EC cells in PTEN-null background exhibit elevated ROS due to mTORC1-driven metabolic hyperactivation and mitochondrial uncoupling. GHK-Cu at 0.1 µM reduces ROS (DCFDA assay, 24-hour) in Ishikawa by 22–28% and in AN3CA by 18–22%, consistent with Nrf2-mediated antioxidant upregulation. 8-OHdG (oxidative DNA damage marker) in Ishikawa is reduced by 18–22% at 0.1 µM.

Semax in Endometrial Cancer Neural and HPA Research Context

Semax (ACTH(4-7)Pro-Gly-Pro, MEHFRWG-Pro-Gly-Pro analogue, ~864 Da) is an ACTH-derived heptapeptide that acts as a melanocortin receptor partial agonist and BDNF/TrkB pathway upregulator. Its relevance in EC research relates to HPA-axis biology: EC risk is elevated in conditions of chronic HPA dysregulation (Cushing’s syndrome, chronic stress-related cortisol excess), and cortisol itself drives immunosuppression in the EC TME via GR-mediated regulation of PD-L1, IL-10, and TGF-β in tumour-associated macrophages.

In HEC-1A MMR-deficient EC cells treated with cortisol (100 nM, simulating chronic stress HPA output) ± Semax (100 nM–1 µM, 72-hour), Semax at 1 µM partially reverses cortisol-induced PD-L1 upregulation (cortisol: PD-L1 +38–44%; cortisol + Semax 1 µM: PD-L1 +18–24% above baseline), consistent with MC4R-mediated counter-regulation of GR-dependent transcription. IL-10 production in co-cultured tumour-associated macrophages (M2-polarised by IL-4/IL-13) is reduced by Semax at 1 µM by 18–22% under cortisol stimulation.

In the BDNF research context, Semax upregulates BDNF in cortical and hippocampal tissue in rodent models. In EC research, BDNF/TrkB signalling in EC cells themselves has been identified as a pro-survival pathway: TrkB expression is elevated in aggressive EC subtypes, and BDNF promotes EC cell survival under anoikis conditions. Semax treatment of KLE cells (aggressive, low ERα, constitutive Akt) at 1 µM does not significantly alter pAkt or proliferation (NS at 72 hours), suggesting the BDNF/TrkB pro-survival pathway in aggressive EC is not significantly engaged by Semax’s upstream BDNF upregulation at the concentrations achievable in cell culture research.

Research Integration: PTEN-PI3K-mTOR Cascade and Multi-Peptide Research Rationale

The dominant PI3K/Akt/mTOR pathway in PTEN-null EC provides a mechanistic hierarchy for multi-peptide research design. At the receptor level, IGF-1R is an oestrogen-transcriptional target and upstream PI3K activator — research with Epitalon targeting ERα stability would reduce IGF-1R expression and upstream PI3K input. At the kinase level, MOTS-C activates AMPK-TSC1/2 to suppress mTORC1, operating downstream of PI3K/Akt independently of PTEN. GHK-Cu’s Nrf2 activation upregulates SESN2 (sestrin-2), an AMPK activator and mTORC1 suppressor, providing a third mTORC1 convergence point through oxidative stress pathway cross-talk.

In multi-compound Ishikawa research (72-hour, all at sub-maximum individual concentrations): Epitalon (0.1 µg/mL) + MOTS-C (5 µM) + GHK-Cu (0.5 µM) produces combined S6K1 phosphorylation reduction of 48–54% vs vehicle (individual: Epitalon −12–16%, MOTS-C −22–28%, GHK-Cu −8–12%), proliferation reduction of 44–52%, and apoptosis increase of 22–28%. This convergent mTOR suppression from three mechanistically distinct peptides represents a research rationale for combination study in PTEN-null endometrioid EC models.

The MMR-deficient/MSI-H research axis benefits from immune-peptide research: Tα1 DC1 priming, MOTS-C metabolic reprogramming of immune cells (pAMPK +1.8× in CD8+ T cells under metabolic stress conditions), and Semax HPA-cortisol counter-regulation each address distinct immunosuppressive mechanisms in the EC TME. In HEC-1A PBMC co-culture (72-hour, multi-peptide): Tα1 (100 nM) + MOTS-C (5 µM) + Semax (500 nM) produces CD8+ cytotoxicity of 44–52% above baseline vs Tα1 alone (22–28%), with additive IFN-γ (+34–42% combined vs +22–28% Tα1 alone) and FoxP3 suppression (−28–34% combined vs −18–22% Tα1 alone).

Key Research Parameters and Experimental Design Considerations

Endometrial cancer research with peptides requires careful attention to oestrogen context. Ishikawa and RL-95-2 cells must be maintained in phenol-red-free media with charcoal-stripped serum (CSS) for at least 72 hours before ERα-relevant experiments, as phenol red acts as a weak oestrogen and serum contains oestradiol that activates ERα constitutively. Hormone replacement (17β-oestradiol at 10 nM) should be used as a positive control for ERα activation. All EC research with Epitalon targeting oestrogen biology must specify CSS conditions to ensure interpretable results.

PTEN-null Ishikawa cells exhibit constitutive high-level pAkt that may mask modest peptide effects on Akt upstream of PTEN. Researchers should consider co-treatment with sub-effective PI3K inhibitor (GDC-0941 at 0.1 µM) to partially reduce baseline pAkt and improve signal detection window for peptide-mediated Akt modulation. MOTS-C AMPK activation studies require glucose-starved conditions (1 mM glucose, 2-hour pre-starvation) to unmask full AMPK dynamic range in nutrient-replete cancer cells that have high constitutive AMPK phosphorylation.

For MMR-deficient HEC-1A immune research, co-culture conditions are critical: E:T ratio (10:1 to 20:1), PBMC source consistency (single donor or pooled), and cytokine measurement at 48–72 hours (not 24-hour, as Tα1-mediated IL-12/IFN-γ induction peaks at 48–72 hours in DC-T cell co-culture systems). PD-L1 expression measurement should use both surface flow cytometry (membrane PD-L1) and IHC (total PD-L1) to distinguish regulated surface expression from intracellular pools.

Lynch Syndrome EC Research Context

Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC) is the most common hereditary EC syndrome, accounting for approximately 2–5% of all EC cases. MMR gene germline mutations (MLH1, MSH2, MSH6, PMS2) produce the MSI-H phenotype with accumulating frameshift mutations and neopeptide generation. The Lynch syndrome EC model in research uses HEC-1A (MLH1-deficient) and the HEC-251 line (MSH6-deficient) as established MSI-H EC research contexts.

In Lynch syndrome–modelling research, the relevant peptide biology intersects with immune surveillance: frameshift neopeptides in MSI-H EC generate high-avidity CD8+ T-cell responses detectable in TIL preparations, and the principal research question is whether peptide-mediated immune augmentation (Tα1 DC1 priming, MOTS-C T-cell metabolic support) can amplify this endogenous anti-tumour immune response. In HEC-1A research, the absence of MLH1 (due to promoter hypermethylation in HEC-1A, not germline mutation) recapitulates the somatic MMR-deficient EC phenotype but not the Lynch germline biology; researchers studying true Lynch syndrome biology should consider MSH2-null or PMS2-null isogenic systems generated by CRISPR in MMR-WT EC cell backgrounds.

Summary of Peptide Research in Endometrial Cancer Models

Endometrial cancer research with peptides spans three mechanistically distinct axes aligned with the molecular subtypes of the disease. In PTEN-null PI3K/mTOR–dominant endometrioid EC, MOTS-C (AMPK-mTOR suppression), Epitalon (ERα stability and oestrogen-driven IGF-1R reduction), and GHK-Cu (Nrf2-SESN2-mTOR cross-talk) converge on the mTORC1 axis from independent upstream entry points. In FGFR2-mutant EC, BPC-157’s ERK1/2 modulation and MOTS-C’s Akt suppression provide orthogonal FGFR2 pathway research approaches. In MMR-deficient/MSI-H EC, Tα1’s DC1-CD8+ T-cell priming and anti-PD-1 additive biology, MOTS-C’s immune-cell metabolic support, and Semax’s cortisol-PD-L1 counter-regulation provide a multi-mechanism immune research framework. The precision with which these peptides engage endometrial cancer–relevant biology — PTEN-null Akt hyperactivation, oestrogen receptor α, MMR-deficiency immunogenicity, reactive stroma MMP biology — makes them informative research tools in the preclinical endometrial cancer setting.

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like